Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine.
This study was undertaken to evaluate the possible role of hepatitis B recombinant vaccine inducing the synthesis of IgG and IgM anti-cardiolipin antibodies (aCL), antibodies against beta(2)GPI (anti-beta(2)GPI), lupus anti-coagulant (LA), anti-nuclear antibodies and antibodies against extractable nuclear antigens (anti-ENA). The study population consisted of 85 healthy students (63 female, 22 male; mean age 20.8 years), vaccinated with three doses of recombinant DNA hepatitis B vaccine. One month after vaccination with the first dose of hepatitis B vaccine a minority of vaccinated individuals showed changes in IgG or IgM aCL or anti-beta(2)GPI or LA activity (P < 0.001). Among subjects in whom changes of IgG anti-beta(2)GPI were observed, a significantly higher number of increased (8/85) than decreased (2/85) values were found (P < 0.01). Analyses of paired data showed that differences in aCL or anti-beta(2)GPI levels before vaccination or 1 month later did not reach statistical significance. In two people aCL transitorily reached medium positivity after the first dose of hepatitis B vaccine with a drop 5 months later. Similar evident anti-beta(2)GPI fluctuation was also observed in one person. Another participant was initially low positive for IgG anti-beta2GPI and the levels were increasing after vaccination. Two participants became positive for anti-nuclear antibodies during 6 months' follow-up. There were no sex-dependent differences in tested antibodies observed and no associations between levels of aPL and levels of anti-HBV antibodies. We conclude that HBV can induce aPL, although rarely. In genetically susceptible individuals or together with some other triggers such combination might confer the risk of developing a continuous autoimmune response in an individual.
Martinuc Porobic
J
J
Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital Ljubljana, Slovenia.
Avcin
T
T
Bozic
B
B
Kuhar
M
M
Cucnik
S
S
Zupancic
M
M
Prosenc
K
K
Kveder
T
T
Rozman
B
B
D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000096:biosynthesis; D017152:Antibodies, Antiphospholipid / Q000096:biosynthesis*; D015551:Autoimmunity; D005260:Female; D006023:Glycoproteins / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D016682:Lupus Coagulation Inhibitor / Q000096:biosynthesis; D008297:Male; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology*; D053482:beta 2-Glycoprotein I
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; C075654:Engerix-B; D006023:Glycoproteins; D017325:Hepatitis B Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016682:Lupus Coagulation Inhibitor; D014614:Vaccines, Synthetic; D053482:beta 2-Glycoprotein I